SIHUAN PHARM Shares Climb Nearly 3% as Subsidiary XUANZHUBIO-B Presents Promising Data on Diraoc in First-Line NSCLC Treatment at AACR

Stock News04-21 11:40

SIHUAN PHARM (00460) rose nearly 3%, with the stock up 2.29% to HK$1.34 at the time of writing. Turnover reached HK$18.04 million. The increase follows an announcement on April 20 that the group's non-wholly owned subsidiary, XUANZHUBIO-B (02575), presented data from the Phase III DIAMOND-2 study of Diraoc as a first-line treatment for ALK-positive advanced non-small cell lung cancer (NSCLC) in an oral presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting, held from April 17 to April 22, 2026.

The data released at the 2026 AACR meeting showed that Diraoc demonstrated statistically significant and clinically meaningful efficacy advantages in the first-line treatment of ALK-positive advanced NSCLC. In the modified intent-to-treat (mITT) population, the investigator-assessed median progression-free survival (mPFS) reached 31.3 months, significantly outperforming the control group's 12.9 months and indicating a 53% reduction in the risk of disease progression (HR=0.47, P<0.0001). Additionally, the Diraoc group achieved an objective response rate (ORR) of 88.5%, a median duration of response (mDoR) of 32.10 months, and a disease control rate (DCR) of 95.4%, with both depth and durability of tumor response significantly superior to those of the control group.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1141536607?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-21 11:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141536607","market":"hk","top_or_hot":-1,"title":"SIHUAN PHARM Shares Climb Nearly 3% as Subsidiary XUANZHUBIO-B Presents Promising Data on Diraoc in First-Line NSCLC Treatment at AACR","media":"Stock News","content":"<p>SIHUAN PHARM (00460) rose nearly 3%, with the stock up 2.29% to HK$1.34 at the time of writing. Turnover reached HK$18.04 million. The increase follows an announcement on April 20 that the group's non-wholly owned subsidiary, XUANZHUBIO-B (02575), presented data from the Phase III DIAMOND-2 study of Diraoc as a first-line treatment for ALK-positive advanced non-small cell lung cancer (NSCLC) in an oral presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting, held from April 17 to April 22, 2026.</p>\n<p>The data released at the 2026 AACR meeting showed that Diraoc demonstrated statistically significant and clinically meaningful efficacy advantages in the first-line treatment of ALK-positive advanced NSCLC. In the modified intent-to-treat (mITT) population, the investigator-assessed median progression-free survival (mPFS) reached 31.3 months, significantly outperforming the control group's 12.9 months and indicating a 53% reduction in the risk of disease progression (HR=0.47, P<0.0001). Additionally, the Diraoc group achieved an objective response rate (ORR) of 88.5%, a median duration of response (mDoR) of 32.10 months, and a disease control rate (DCR) of 95.4%, with both depth and durability of tumor response significantly superior to those of the control group.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SIHUAN PHARM Shares Climb Nearly 3% as Subsidiary XUANZHUBIO-B Presents Promising Data on Diraoc in First-Line NSCLC Treatment at AACR</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSIHUAN PHARM Shares Climb Nearly 3% as Subsidiary XUANZHUBIO-B Presents Promising Data on Diraoc in First-Line NSCLC Treatment at AACR\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-21 11:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SIHUAN PHARM (00460) rose nearly 3%, with the stock up 2.29% to HK$1.34 at the time of writing. Turnover reached HK$18.04 million. The increase follows an announcement on April 20 that the group's non-wholly owned subsidiary, XUANZHUBIO-B (02575), presented data from the Phase III DIAMOND-2 study of Diraoc as a first-line treatment for ALK-positive advanced non-small cell lung cancer (NSCLC) in an oral presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting, held from April 17 to April 22, 2026.</p>\n<p>The data released at the 2026 AACR meeting showed that Diraoc demonstrated statistically significant and clinically meaningful efficacy advantages in the first-line treatment of ALK-positive advanced NSCLC. In the modified intent-to-treat (mITT) population, the investigator-assessed median progression-free survival (mPFS) reached 31.3 months, significantly outperforming the control group's 12.9 months and indicating a 53% reduction in the risk of disease progression (HR=0.47, P<0.0001). Additionally, the Diraoc group achieved an objective response rate (ORR) of 88.5%, a median duration of response (mDoR) of 32.10 months, and a disease control rate (DCR) of 95.4%, with both depth and durability of tumor response significantly superior to those of the control group.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1593","symbol_name":"医美概念股","start_time":0,"source_url":"","article_id":"1141536607","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141536607","pubTimestamp":1776742822,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SIHUAN PHARM (00460) rose nearly 3%, with the stock up 2.29% to HK$1.34 at the time of writing. Turnover reached HK$18.04 million. The increase follows an announcement on April 20 that the group's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1593":"医美概念股","BK1515":"抗疫概念","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1191":"制药","VXUS":"国际股票ETF-Vanguard","BK1600":"工业大麻","02575":"轩竹生物-B","00460":"四环医药"},"translate_title":"四环医药股价上涨近3%，子公司轩竹生物-B在AACR上展示了Diraoc一线非小细胞肺癌治疗的有希望的数据","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"02575":1,"00460":1},"content_text":"SIHUAN PHARM (00460) rose nearly 3%, with the stock up 2.29% to HK$1.34 at the time of writing. Turnover reached HK$18.04 million. The increase follows an announcement on April 20 that the group's non-wholly owned subsidiary, XUANZHUBIO-B (02575), presented data from the Phase III DIAMOND-2 study of Diraoc as a first-line treatment for ALK-positive advanced non-small cell lung cancer (NSCLC) in an oral presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting, held from April 17 to April 22, 2026.\nThe data released at the 2026 AACR meeting showed that Diraoc demonstrated statistically significant and clinically meaningful efficacy advantages in the first-line treatment of ALK-positive advanced NSCLC. In the modified intent-to-treat (mITT) population, the investigator-assessed median progression-free survival (mPFS) reached 31.3 months, significantly outperforming the control group's 12.9 months and indicating a 53% reduction in the risk of disease progression (HR=0.47, P<0.0001). Additionally, the Diraoc group achieved an objective response rate (ORR) of 88.5%, a median duration of response (mDoR) of 32.10 months, and a disease control rate (DCR) of 95.4%, with both depth and durability of tumor response significantly superior to those of the control group.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1141536607","isCrawlerRequest":true}